Since we are strongly convinced about the diagnostic biomarker potential of TRPC3 and TRPC7 transcript abundancy in tumor specimens, targeted attempts via rapid-to-apply technologies such as RT-qPCR or target-amplification free CRISPR/Cas diagnostics instead of OMICS-acquisition would enable better applicability/dissemination potential of our markers. The gene discussed is TRPC3; the disease is neoplasm.